SUPN
Closed
Supernus Pharmaceuticals Inc
31.82
+0.30 (+0.95%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 31.52
Day's Range: 31.37 - 32.78
Send
sign up or login to leave a comment!
When Written:
36.91
Supernus Pharmaceuticals Inc is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Supernus' product portfolio includes treatments for epilepsy, attention deficit hyperactivity disorder (ADHD), and migraine. Its lead products include Oxtellar XR, a once-daily extended-release tablet for the treatment of partial seizures in adults and children; and Trokendi XR, a once-daily extended-release capsule for the treatment of epilepsy and migraine in adults and children.
The company also has a pipeline of product candidates in various stages of development for the treatment of CNS disorders, including ADHD, depression, and epilepsy.
Supernus is committed to improving patient outcomes and enhancing the quality of life for individuals living with CNS disorders. The company's mission is to be a leading CNS pharmaceutical company that delivers innovative and differentiated products to patients and healthcare professionals.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Supernus' product portfolio includes treatments for epilepsy, attention deficit hyperactivity disorder (ADHD), and migraine. Its lead products include Oxtellar XR, a once-daily extended-release tablet for the treatment of partial seizures in adults and children; and Trokendi XR, a once-daily extended-release capsule for the treatment of epilepsy and migraine in adults and children.
The company also has a pipeline of product candidates in various stages of development for the treatment of CNS disorders, including ADHD, depression, and epilepsy.
Supernus is committed to improving patient outcomes and enhancing the quality of life for individuals living with CNS disorders. The company's mission is to be a leading CNS pharmaceutical company that delivers innovative and differentiated products to patients and healthcare professionals.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








